



MANAGEMENT DISCUSSION AND ANALYSIS
FOR THE THREE MONTHS AND TWELVE MONTHS ENDED DECEMBER 31, 2023.

FORWARD LOOKING STATEMENTS

This MD&A contains certain statements that may constitute “forward-looking statements”. Forward-looking statements include but are not limited to, statements regarding future anticipated business developments and the timing thereof, regulatory compliance, sufficiency of working capital, and business and financing plans. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made, and they involve several material risks and uncertainties. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate, and similar expressions, or which by their nature refer to future events. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future performance, and that actual results may differ materially from those in forward looking statements because of various factors, including, but not limited to, the Company’s ability to continue its projected growth, to raise the necessary capital or to be fully able to implement its business strategies.

The Company has based the forward-looking statements largely on the Company's current expectations, estimates, assumptions, and projections about future events and financial and other trends that the Company believes, as of the date of such statements, may affect its business, financial condition, and results of operations. Such expectations, estimates, assumptions, and projections, many of which are beyond the Company’s control, include, but are not limited to: management’s expectations regarding the future business, objectives and, operations of the Company; the Company’s anticipated cash needs and the need for additional financing; the Company’s ability to successfully complete future financings; the acceptance by the marketplace of new technologies and solutions; the Company’s expectations regarding its competitive position; the Company’s expectations regarding regulatory developments and the impact of the regulatory environment in which the Company operates; the Company’s ability to attract and retain qualified management personnel and key employees; and anticipated trends and challenges in the Company’s business and the markets in which it operates. Assumptions underlying the Company's working capital requirements are based on management's experience with other public companies.

Forward-looking statements regarding treatment by governmental authorities assumes no material change in regulations, policies, or the application of the same by such authorities. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made, and readers are advised to consider such forward-looking statements with the risks set forth.

The following Management’s Discussion and Analysis (“MD&A”) of Leveljump should be read in conjunction with the Company’s audited Consolidated Financial Statements for the period ended December 31, 2023, together with notes thereto (the “Financial Statements”). The Company’s audited Consolidated Financial Statements for the period ended December 31, 2023, have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) and interpretations issued by the IFRS Interpretations Committee (“IFRIC”). All amounts herein are presented in Canadian dollars, unless otherwise noted. This Management’s Discussion and Analysis is dated August 09, 2024, and has been approved by the Board of Directors of the Company.

The Company's Audited Consolidated Financial Statements and its Annual Information Form are available on SEDAR at www.sedar.com

OVERALL PERFORMANCE

Summary of Business

Leveljump Healthcare Corp. ("LevelJump" or the "Company") is incorporated under the Ontario Business Corporations Act. The Company's registered head office is 52 Scarsdale Road, Suite 207, Toronto, Ontario, M3B 2R7. The Company's website is www.leveljumphealthcare.com.

The Company's principal business activity is providing radiology services both by providing direct patient images and by providing Teleradiology services. Teleradiology is the process of providing remote off site reading of radiology scans such as CT, MRI, US, and X-ray. Hospital staff scan their emergency room patients, then page the Company's radiologist on call, who can then remotely view, via secured server, the images and diagnose the patient and provide a report back to the hospital.

Results for Q4 2023

Total revenues for the fourth quarter were strong at \$3,895,197. Revenue for the twelve months ended was \$12,582,047, a year over year increase of over 31%.

Teleradiology & Admin revenues for the quarter were \$2,344,660 which was an increase of 6.2% compared to the fourth quarter of 2022. The demand for CTS services is strong. Hospitals are trying to open access to more imaging overnight for their ER departments, which would increase the patient scan volume that CTS reads. Client hospitals have had some issues with staffing, and as the problem is resolved, we anticipate volume to increase further.

Revenues at the Company's IHF's totalled \$1,550,538 in the fourth quarter an increase over the fourth quarter of 2023. Patient visits are increasing and demands for services remains strong.

The Company did experience a tight labour pool, as is the experience with the broader healthcare market in Ontario. Efforts continue to recruit additional radiologists to ensure fluidity in coverage.

Industry Events and Trends

In Ontario there is a continuation of a tight labour force in health care, including in the fields of radiology and medical imaging technologists. There were some minor tweaks implemented by the provincial government in the last year but not enough to alleviate the situation.

The Ontario government made a change to allow women from the age of 40-49 to have bi-annual mammography examinations starting in October 2024. This lowers the age for testing by ten years, as current policy has been for women 50 years and older to be eligible for breast screening. The Ontario government estimates that within the first couple of years it will add at least another 130,000 mammography scans per year, provincially. It is expected that other provinces may also adopt this change as a policy encourage proactive health care.

The Ontario provincial government was working on its plans on the call for MRI and CT licenses, but little new guidance was provided in 2023, other than an indication that in the spring of 2024 more information would be made available.

Alberta faces some of the labour constraints seen in Ontario and the rest of Canada. This creates a competitive market for doctors and technologists, applying pressure on wages and growth.

Canada is showing a strong growth rate with an increased demand for imaging services. This includes a need for greater access, in creased emergency care and quick turnaround times for results. This trend continues to increase nationally with few new modalities and clinics coming on-line.

Outlook

2023 was a strong and important year for the Company as we continue to grow. This was highlighted by our acquisition of ADC Imaging inc. in Alberta that is expected to add over \$4.8m per year in revenues. This acquisition along with the organic growth within our existing operations, allowed us to increase our revenue by more than 30% for the year.

For 2024, the company continues to grow. Focus will be on marketing and the expansion of services at all our clinics. Our Ontario clinics look at ways to expand hours to fill the demand in their communities. The newest clinic, YSXU, is being built and will open in the third quarter of the year, providing x-ray and ultrasound services. Management believes this new clinic is in a prime Toronto location and as such has built the facility to act as a flagship location that we plan will also integrate with our future Telehospital portal.

Our Alberta locations look to maximize revenue by adding staff, adding more modalities, marketing and outreach within our referring physician offices.

Teleradiology demand is expected to remain strong in 2024 as hospital emergency rooms are finding it difficult to keep up with the growing volumes and need for diagnostic imaging. CTS will focus on recruiting additional radiologists to help grow our hospital services.

In addition to our core radiology services, there will also be a focus on continuing development of our Telehospital portal.

Financing and Share Issuances (See Notes 14, 17 in Financial Statements)

During the year ended December 31, 2023, the Company issued 9,205,000 shares of common stock for proceeds of \$599,958 as well as 2,005,000 Class A-1 preferred shares for net proceeds of \$1,760,400. Additionally, the Company was able to raise \$3,696,933 through bank and equipment loans.

LIQUIDITY AND CAPITAL RESOURCES

As of December 31, 2023, the Company had cash and cash equivalents in the amount of \$72,247 (December 31, 2022 - \$84,613).

The Company's current assets as of December 31, 2023, excluding cash and cash equivalents were \$2,259,892 (December 31, 2022 - \$2,180,706) which consisted of accounts receivable in the amount of \$1,358,507 (December 31, 2022 - \$1,359,641), due from related parties in the amount of \$696,152

(December 2022 - \$625,682) and prepaid expenses and deposits totalling \$205,233 (December 31, 2022 - \$195,382).

Current liabilities as of December 31, 2023, were \$4,273,996 (December 31, 2022 - \$1,898,247) which were comprised of accounts payables and accrued liabilities of \$2,717,074 (December 31, 2022 - \$1,275,536), operating line of credit \$148,683 (December 2022 - \$147,129), preferred dividends payable \$91,740 (December 2022 \$nil), current portion of lease liabilities \$542,065 (December 31, 2022 - \$108,303) and current portion of long-term debt \$774,435 (December 31, 2022 - \$367,279).

The continuing operations of the Company are dependent upon its ability to raise adequate financing and to continue its operations in the future. For the year ended December 31, 2023, the Company had a comprehensive loss/net income of (\$2,208,117) and as of December 31, 2023, an accumulated deficit of (\$16,687,685). These uncertainties may cast significant doubt upon the Company's ability to continue as a going concern.

Although the Company has been successful in borrowing funds or raising equity capital in the past, there can be no assurance that the Company will have sufficient financing to meet its future capital requirements, or that additional financing will be available on terms acceptable to the Company in the future. The Company has and may continue to have capital requirements more than its currently available resources.

CAPITAL RESOURCES

The Company defines capital as total shareholders' equity and long-term debt. The Company manages its capital structure, based on the funds available to the Company, to support the growth and development of its operations and bring new products to market and to ensure it continues as a going concern. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company will continue to assess new opportunities and seek to acquire an interest in growth situations if it feels there is sufficient economic potential and if it has adequate financial resources to do so.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There were no changes in the Company's approach to capital management during the year ended December 31, 2023. The Company is not subject to externally imposed capital requirements other than those on its Long-Term Debt which include priority rights against CTS, maintaining a debt to adjusted EBITDA ratio of 3.5x times as of December 31, 2023, and maintaining a debt service coverage ratio of not less than 115%.

OFF-BALANCE SHEET ARRANGEMENTS

The Company does not have any Off-Balance Sheet arrangements.

RELATED PARTY TRANSACTIONS AND BALANCES

Related parties include key management being the Company's executive officers, the Board of Directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions. The details of related party transactions can be found in the Company's financial statements Note 21.

FOURTH QUARTER RESULTS

Quarter Ended	December 31, 2023	December 31, 2022
Total revenue	\$3,895,197	\$2,628,327
Gross margin	1,124,583	463,739
Operating Expenses	1,095,827	466,591
Net (loss) / income	(216,708)	(49,271)
Loss per share—basic and diluted	\$(0.002)	\$(0.000)

REVENUES

Teleradiology

For the three months ended December 31, 2023, the Company's teleradiology revenue increased by \$125,686 to \$2,344,660 compared to \$2,218,973 for the same period in 2022.

Diagnostic Imaging Services

For the three months ended December 31, 2023, the Company's Diagnostic Imaging Services revenue was \$1,550,538 increased by \$1,141,184 compared to \$409,354 for the same period in 2022.

TOTAL REVENUE

Total revenue for the three months December 31, 2023, was up \$1,266,870 to \$3,895,197 compared to \$2,628,327 for the three months ended December 31, 2022. The increase in total revenue is primarily a result of the revenues generated from increased diagnostic imaging services due to the acquisition of additional centres in October 2023.

COST OF SALES

Physician Fees

For the three months ended December 31, 2023, the Company's physician fees totaled \$2,033,064 higher by \$338,256 compared to physician fees of \$1,694,808 for the three months ended December 31, 2022. The increase in reading fees in the current three-month period is a result of the increased operations due to increased demand for the Company's services and the acquisition of additional centres in October 2023.

Cost of Labour

For the three months ended December 31, 2023, the Company's technician fees totaled \$268,171 decreased by \$(12,255) compared to \$280,425 for the same period in 2022. Due primarily to the acquisition of additional centres in October 2023.

Cost of Supplies

PACS costs for the three months ended December 31, 2023, was \$87,543 compared to \$70,203 for the three-month period ended December 31, 2022. This increase was related to patient volume at the

diagnostic centres. Additionally, the increased costs are partially offset by amounts we can collect in administrative revenues.

Other Cost of Services

For the three months ended December 31, 2023, the Company's other cost of services totaled \$102,328 an increase of \$74,310 compared to \$28,018 in the same period December 31, 2022.

Repairs & Maintenance

For the three months ended December 31, 2023, the Company's repairs & maintenance costs totaled \$38,628 an increase of \$21,167 compared to \$17,461 in the same period December 31, 2022.

Amortization

For the three months ended December 31, 2023, the Company's amortization costs totaled \$125,345 an increase of \$99,718 compared to \$25,627 in the same period December 31, 2022.

Depreciation

For the three months ended December 31, 2023, the Company's depreciation costs totaled \$115,534 an increase of \$67,489 compared to \$48,045 in the same period December 31, 2022.

TOTAL COST OF SALES

Total cost of sales during the fourth quarter in 2023 including physician fees, cost of labour, cost of supplies, other cost of services, repairs and maintenance, amortization and depreciation totalled \$2,770,614 compared to \$2,164,588 an increase of \$606,026. Higher cost of sales experienced during the fourth quarter in 2023, was primarily a result of costs associated with the IHF acquisition in addition to increased operations due to higher demand for the Company's services.

GROSS PROFIT

As a result of the above revenues net of cost of sales, the Company's gross margin increased by \$660,844 to \$1,124,583 for the three-month period ending December 31, 2023, versus gross margin of \$463,739 for the same three-month period in 2022.

EXPENSES

Stock Based Compensation

For the three months ended December 31, 2023, the Company recorded stock-based compensation of \$nil compared to \$36,833 for the same period in December 2022.

Salaries and Wages

For the three months ended December 31, 2023, the Company recorded salaries and wages of \$412,114 compared to \$7,105 for the same three-month period ended December 2022. This change was primarily due to salary and wages being reclassified into Cost of Labour.

Professional Fees

For the three months ended December 31, 2023, the Company recorded professional fees of \$452,974 up considerably, by \$151,128, compared to \$301,847 for the three months ended December 31, 2022. The

increase in professional fees for the three months ended December 31, 2023, was primarily attributed to increased consulting fees in the fourth quarter due to revisions in management compensation contracts.

General and Administrative

General and administrative costs totaled \$172,614 up \$85,594 for the three months ended December 31, 2023, compared to general and administrative costs of \$87,020 for the same three-month period in 2022. The Company experienced an increase in general and administrative costs during the current period in fiscal 2023, because of additional expenses incurred by the IHF centres.

Insurance

Insurance expense for the three months ended December 31, 2023, increased by \$2,258 to \$20,040 when compared to \$17,782 for the same period in 2022.

Depreciation and Amortization

For the three months ended December 31, 2023, depreciation and amortization costs totaled \$21,285 for the same period in 2022 \$nil.

Listing Expense

For the three months ended December 31, 2023, the Company's listing expense costs increased by \$796 to \$16,800 compared to \$16,004 for the same period in 2022.

TOTAL OPERATING EXPENSES

Total expenses for the three months ended December 31, 2023, were \$1,095,827, higher by \$629,236 when compared to total expenses of \$466,591 for the three months ended December 31, 2022.

OTHER INCOME

For the three months ended December 31, 2023, other income was \$nil for miscellaneous income, whereas in 2022 for the same period it was \$2,500.

OTHER EXPENSES

Interest Expense

For the three months ended December 31, 2023, the Company recorded interest expense of \$190,847 which increased by \$147,622 versus the interest expense of \$43,225 for the three-month period ended December 31, 2022. The increase in interest expense during 2023 was primarily related to interest on the bank Loans.

Income Tax

For the three months ended December 31, 2023, the Company recorded the income tax at (\$598) whereas in 2022 for the same period it was \$nil. The income tax recorded in 2023 were related to a write-off that were no longer due.

Gain/Loss on Fixed Assets

For the three months ended December 31, 2023, the Company recorded the gain/loss on fixed assets at \$19,014 whereas in 2022 for the same period it was \$nil.

Other Miscellaneous Expenses

For the three months ended December 31, 2023, the Company recorded miscellaneous expenses at (\$9,299) whereas in 2022 for the same period it was \$1,733.

Foreign Exchange Loss

For the three months ended December 31, 2023, the foreign exchange loss was \$nil in the fourth quarter of 2023. In the fourth quarter of 2022 foreign exchange loss was recorded for \$425.

TOTAL EXPENSES

Total expenses for the three months ended December 31, 2023, were \$245,464, increased by \$196,545 compared to \$48,919 for the three-month period ended December 31, 2022. The increase in total expenses for the three-month period ended December 31, 2023, was primarily related to professional fees, salaries and wages, depreciation & amortization, insurance and general & administrative.

NET LOSS AND COMPREHENSIVE LOSS

As a result of the above factors, the net loss and comprehensive loss for the three months ended December 31, 2023, was (\$216,708) compared to a net income and comprehensive loss of (\$49,271) for the three months ended December 31, 2022.

TWELVE MONTH RESULTS

Period Ended	December 31, 2023	December 31, 2022
Total revenue	\$ 12,582,047	\$ 9,227,752
Gross margin	2,355,260	1,573,955
Operating Expenses	3,178,521	2,374,896
Net (loss) / income	\$ (2,208,117)	\$ 185,011
Income/(Loss) per share—basic and diluted	\$(0.024)	\$0.002

REVENUES

Teleradiology

For the twelve months ended December 31, 2023, the Company's teleradiology revenue increased by \$2,001,598 to \$9,715,357 compared to \$7,713,758 in 2022.

Diagnostic Imaging Services

For the twelve months ended December 31, 2023, the Company's Diagnostic Imaging Services revenue was \$2,866,691 an increase of \$1,352,697 compared to \$1,513,994 in the same period in 2022.

TOTAL REVENUE

Total revenue for the twelve months December 31, 2023, was up \$3,354,295 to \$12,582,047 compared to \$9,227,752 for the twelve months ended December 31, 2022. The increase in total revenue is primarily a result of the increased teleradiology revenue and the revenue produced from the acquisition of additional centres in October 2023.

COST OF SALES

Physician Fees

For the twelve months ended December 31, 2023, the Company's physician fees totaled \$7,717,579 higher by \$1,772,116 compared to physician fees of \$5,945,463 for the three months ended December 31, 2022. The increase in reading fees in the current twelve-month period is a result of the increased operations due to increased demand for the Company's services and the acquisition of additional centres in October 2023.

Cost of Labour

For the twelve months ended December 31, 2023, the Company's technician fees totaled \$1,374,937 increased by \$349,855 compared to \$1,025,081 for the same period in 2022.

Cost of Supplies

PACS costs for the twelve months ended December 31, 2023, was \$295,560 increased by \$67,370 compared to \$228,190 for the twelve-month period ended December 31, 2022. This increase was related to patient volume at the diagnostic centres.

Other Cost of Services

For the twelve months ended December 31, 2023, the Company's other cost of services totaled \$233,792 an increase of \$121,154 compared to \$112,638 in the same period December 31, 2022.

Repairs & Maintenance

For the twelve months ended December 31, 2023, the Company's repairs & maintenance costs totaled \$90,730 an increase of \$32,710 compared to \$58,020 in the same period December 31, 2022.

Amortization

For the twelve months ended December 31, 2023, the Company's amortization costs totaled \$256,567 an increase of \$148,150 compared to \$108,417 in the same period December 31, 2022.

Depreciation

For the twelve months ended December 31, 2023, the Company's depreciation costs totaled \$257,622 an increase of \$81,635 compared to \$175,987 in the same period December 31, 2022.

TOTAL COST OF SALES

Total cost of sales during the year in 2023 including physician fees, cost of labour, cost of supplies, other cost of services, repairs and maintenance, amortization and depreciation totalled \$10,226,787 compared to \$7,653,797 an increase of \$2,572,990. Higher cost of sales experienced during the year in 2023, was primarily a result of costs associated with the IHF acquisition in addition to increased operations due to higher demand for the Company's services.

GROSS PROFIT

As a result of the above revenues net of cost of sales, the Company's gross margin increased by \$781,305 to \$2,355,260 for the twelve-month period ending December 31, 2023, versus gross margin of \$1,573,955 for the same twelve-month period in 2022.

EXPENSES

Stock Based Compensation

For the twelve months ended December 31, 2023, the Company recorded stock-based compensation of \$nil compared to \$293,332 for the same period in 2022.

Salaries and Wages

For the twelve months ended December 31, 2023, the Company recorded salaries and wages of \$501,156 compared to \$335,234 for the same twelve-month period ended December 2022.

Professional Fees

For the twelve months ended December 31, 2023, the Company recorded professional fees of \$1,989,258 up considerably, by \$679,442, compared to \$1,309,816 for the twelve months ended December 31, 2022. The increase in professional fees for the twelve months ended December 31, 2023, was primarily attributed to increased consulting fees in the fourth quarter due to revisions in management compensation contracts.

General and Administrative

For the twelve months ended December 31, 2023, general and administrative costs totaled \$440,208 up \$196,448 for the twelve months ended December 31, 2023, compared to general and administrative costs of \$243,720 for the same twelve-month period in 2022. The Company experienced an increase in general

and administrative costs during the current period in fiscal 2023, because of additional expenses incurred by the IHF centres.

Insurance

For the twelve months ended December 31, 2023, Insurance expense for the twelve months ended December 31, 2023, increased by \$263 to \$75,874 when compared to \$75,611 for the same period in 2022.

Depreciation and Amortization

For the twelve months ended December 31, 2023, depreciation and amortization costs totaled \$85,138 for the same period in 2022 \$nil.

Listing Expense

For the twelve months ended December 31, 2023, the Company's listing expense costs decreased by - (\$30,297) to \$86,886 compared to \$117,183 for the same period in 2022.

TOTAL OPERATING EXPENSES

Total expenses for the twelve months ended December 31, 2023, were \$3,178,521, higher by \$803,626 when compared to total expenses of \$2,374,896 for the twelve months ended December 31, 2022. The primary factors relating to the increase in total expenses during the year in 2023 were due the increase professional fees \$679,442, general & administrative \$196,448, salary and wages \$165,922 and depreciation & amortization \$85,138.

OTHER INCOME

For the twelve months ended December 2023, other income was \$2,604, whereas in 2022 for the same period it was \$1,144,932.

OTHER EXPENSES

Interest Expense

For the twelve months ended December 31, 2023, the Company recorded interest expense of \$399,415 which increased by \$255,832 versus the interest expense of \$143,583 for the twelve-month period ended December 31, 2022. The increase in interest expense during 2023 was primarily related to interest on the Loans.

Loss on Sale of Investments

For the twelve months ended December 31, 2023, the Company recorded the loss on sale of investments at \$1,087,096 whereas in 2022 for the same period it was \$nil.

Income Tax

For the twelve months ended December 31, 2023, the Company recorded the income tax at \$8,604 whereas in 2022 for the same period it was \$nil. The income tax recorded in 2023 were related to a write-off that were no longer due.

Broker Commissions

For the twelve months ended December 31, 2023, the Company recorded broker commission at \$nil whereas in 2022 for the same period it was \$23,736.

Gain/Loss on Fixed Assets

For the twelve months ended December 31, 2023, the Company recorded the gain/loss on fixed assets at \$19,014 whereas in 2022 for the same period it was \$4,626 an increase of \$14,388.

Other Miscellaneous Expenses

For the twelve months ended December 31, 2023, the Company recorded miscellaneous expenses at (\$12,169) whereas in 2022 for the same period it was (\$16,350).

Foreign Exchange Loss

For the twelve months ended December 31, 2023, the foreign exchange loss was \$396 in the fourth quarter of 2023. In the fourth quarter of 2022 foreign exchange loss was recorded for \$3,385 a decrease of (\$2,990).

TOTAL EXPENSES

Total expenses for the twelve months ended December 31, 2023, were \$1,387,460, increased by \$1,228,480 compared to \$158,980 for the twelve-month period ended December 31, 2022. The increase in total expenses for the twelve-month period ended December 31, 2023, was primarily related to professional fees, cost of labour, cost of supplies, other cost of services, repairs and maintenance, depreciation & amortization.

NET LOSS AND COMPREHENSIVE LOSS

As a result of the above factors, the net loss and comprehensive Income for the twelve months ended December 31, 2023, was \$(2,208,117) compared to a net loss and comprehensive loss of 185,011 for the twelve months ended December 2022, a decrease of \$(2,393,128).

LOSS PER SHARE – BASIC AND DILUTED

The loss per share-basic and diluted for the twelve months ended December 31, 2023, was \$(0.024) versus the loss per share-basic and diluted of \$0.002 for the comparable period in 2022.

PROPOSED TRANSACTIONS

The Company does not have any proposed transactions.

CHANGES IN ACCOUNTING POLICIES

The Company reclassified some Operating Expenses into Cost of Services.

FINANCIAL INSTRUMENTS AND OTHER INSTRUMENTS

During 2023 the Company had various bank loans outstanding as well as equipment loans. The interest rates on the loans vary from 6.28% to 9.99%. The bank loans are secured by a general security agreement representing a first charge on all the Company's present and future acquired assets. The equipment loan is secured by medical equipment specifically assigned by the Company. The bank loans have a 5-year term, are due in 2027, and are amortized over 10 years. The Equipment loans are amortized over 5 years and are due in 2028.

Credit risk

Credit risk is the risk of loss associated with a counter-party's inability to fulfill its payment obligations. The Company's cash and accounts receivable are exposed to credit risk. Jump's cash is held with a major Canadian-based financial institution and as such management believes that the associated credit risk is remote.

Account receivables represent revenue earned from services rendered to hospitals. The Company has adopted a credit policy under which each new customer is analyzed individually for creditworthiness before the Company's standard payment terms and conditions are offered.

The Company's trade receivables are concentrated among customers in the healthcare industry, which may be affected by adverse government policy impacting that industry. As of December 31, 2023, four customers accounted for greater than 50% of the Company's trade receivable balance.

There have been no material changes to this risk exposure from 2022.

The Company's maximum exposure to credit risk as of December 31, 2023, and December 31, 2022, was as follows:

	December 31, 2023	December 31, 2022
Cash and Cash Equivalents	\$ 72,247	84,613
Accounts Receivable	1,358,507	1,359,641
Loans Receivable	696,152	625,682
Prepaid Expenses and Deposits	205,233	195,382
Total	\$2,332,139	\$2,265,319

SHARE CAPITAL AND RESERVES

Authorized Share Capital

As at the date of filing this report the Company had 96,424,729 common shares outstanding. There are no other approved classes of shares for the Company. (Financial Statements Note 17)

Stock Options

As at the date of filing this report the Company had 3,600,000 options issued and outstanding all are vested and exercisable into shares of common stock. (Financial Statements Note 18)

Warrants

As at the date of filing this report the Company had 33,214.927 common share purchase warrants issued and outstanding. (Financial Statements Note 19)

Class A-1 Preferred Shares

As at the date of filing this report the Company had 2,094,000 Class A-1 preferred shares issued and outstanding. (Financial Statements Note 17)